-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MB86tjmtd7YdBo9hhZeOgGfZ/+0oKM9ltdWV3/uAeZaw0jlo9XHaGXZ4XKYPnI/1 GvazJXyaDoReO3dS9MKc+g== 0000062391-98-000006.txt : 19980402 0000062391-98-000006.hdr.sgml : 19980402 ACCESSION NUMBER: 0000062391-98-000006 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 19980401 SROS: NASD GROUP MEMBERS: HMR PHARMA, INC. GROUP MEMBERS: HOECHST MARION ROUSSEL INC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL GENESYS INC CENTRAL INDEX KEY: 0000865231 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943061375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-43085 FILM NUMBER: 98584938 BUSINESS ADDRESS: STREET 1: 322 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 4153589600 MAIL ADDRESS: STREET 1: 322 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G 1 CELL GENESYS 13D =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CELL GENESYS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 150921 10 4 ----------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would later the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) =========================================================================== Page 1 of 10 Exhibit Index is located at page 9 2 CUSIP No. 150921 10 4 ___________________________________________________________________________ 1) Name of Reporting Person and its Hoechst Marion Roussel, Inc. I.R.S. Identification Number 44-0565557 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 2,750,000* Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 2,750,000* Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 2,750,000* by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 9.52% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. 3 CUSIP No. 150921 10 4 13G ___________________________________________________________________________ 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 2,750,000* Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 2,750,000* Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 2,750,000* by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 9.52% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. 4 CUSIP No. 150921 10 4 13G This Statement on Schedule 13G (the "Schedule 13G") with respect to the Common Stock of Cell Genesys, Inc. (the "Issuer"), is filed jointly by Hoechst Marion Roussel, Inc., a Delaware corporation ("HMRI"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), to replace the Schedule 13D previously filed by the reporting persons, who have determined pursuant to SEC Rule 13d-1(h) that the provisions of paragraphs (e), (f), and (g) of Rule 13d-1 do not apply. ITEM 1(a). NAME OF ISSUER: - ---------- --------------- Cell Genesys, Inc. ITEM 1(b). ADDRESS OF ISSUER S PRINCIPAL EXECUTIVE OFFICES: - ---------- ------------------------------------------------ 322 Lakeside Drive Foster City, CA 94404 ITEM 2(a). NAME OF PERSON FILING: - ---------- ---------------------- Hoechst Marion Roussel, Inc. HMR Pharma, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ---------- ------------------------------------------------------------ Hoechst Marion Roussel, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - ---------- ------------ Delaware As To Both Hoechst Marion Roussel, Inc. And HMR Pharma, Inc. ITEM 2(d). TITLE OF CLASS OF SECURITIES: - ---------- ----------------------------- Common Stock, $.001 Par Value 5 CUSIP No. 150921 10 4 13G ITEM 2(e): CUSIP NUMBER: - ---------- ------------- 150921 10 4 ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR 13D-2(b): - ------- ------------------------------------------------------- Not Applicable ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: As Of 12/31/97 2,000,000 Shares Of Common Stock And A Warrant To Purchase Up To 750,000 Warrant Shares At $13.00 Per Share During The Period Beginning 11/27/1995 And Ending 10/09/2000. (b): PERCENT OF CLASS: 9.52% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 2,750,000* (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the 2,750,000* disposition of: (iv) Shared power to dispose or to direct the 0 disposition of: * Includes up to 750,000 shares that may be purchased for $13.00 per share upon the exercise of a Common Stock Purchase Warrant during the period beginning November 27, 1995, and ending October 9, 2000. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS - ------- --------------------------------------------- Not Applicable 6 CUSIP No. 150921 10 4 13G ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. - ------- ---------------------------------------------------------------- Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH - ------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY --------------------------------------------------------------- Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP - ------- --------------------------------------------------------- Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. - ------- ------------------------------- Not Applicable ITEM 10. CERTIFICATION. - -------- -------------- Not Applicable 7 CUSIP No. 150921 10 4 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 17, 1998 --------------------------------- (Date) HOECHST MARION ROUSSEL, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 8 CUSIP No. 150921 10 4 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 17, 1998 --------------------------------- (Date) HMR PHARMA, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 9 CUSIP No. 150921 10 4 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated March 10 17, 1998, by and between Hoechst Marion Roussel, Inc. and HMR Pharma, Inc. EX-99 2 EXHIBIT 99.A TO CELL GENESYS 13D 10 CUSIP No. 150921 10 4 13G EXHIBIT 99. A ------------- AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G and all subsequent amendments thereto executed by both of us are filed on behalf of each of us. HOECHST MARION ROUSSEL, INC. March 17, 1998 /s/ Rebecca R. Tilden - --------------------------- ------------------------------------- (Date) (Name and Title) Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. March 17, 1998 /s/ Rebecca R. Tilden - --------------------------- ------------------------------------- (Date) (Name and Title) Rebecca R. Tilden Vice President and Secretary -----END PRIVACY-ENHANCED MESSAGE-----